The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

Fortunately, my home isn't too far from Stamford Bridge stadium, making it easy to catch the action live! Connect with Peter ...

US biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...

Roughly 61,000 Georgians live with HIV, the sexually transmitted virus (STI) that can lead to AIDS, and Atlanta ranks in the ...

CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...